Literature DB >> 31014508

Breast cancer risk of hormonal contraception: Counselling considering new evidence.

Lino Del Pup1, Giovanni Codacci-Pisanelli2, Fedro Peccatori3.   

Abstract

The possibility that the use of hormonal contraceptives may increase the risk of breast cancer has been raised since many years. In the past this hypothesis has been dismissed on the basis that available data were generally derived from "old" studies in which relatively high hormone doses had been used. The recent publication of two studies that analysed data from women receiving low-dose hormonal contraception and showed a statistically significant increase in breast cancer contradicts this reassuring belief. The topic however is not settled, since different results were obtained in other studies and since hormonal contraception (HC) also has unquestionable positive effects such as a decrease in ovarian and in endometrial cancer. The aim of the present paper is to provide evidence that may help gynaecologists and oncologists in discussing with their patients the use of HC. Even if cancer phobia is a strong reason for not using or limiting HC, patients must be informed that notwithstanding the slightly increased breast cancer risk, the overall cancer risk may still be lower than non-users. Proper counselling may help the woman choose the most suitable contraception in the different phases of her life and on the basis of other conditions that may increase cancer risk such as overweight, smoking or family history.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer risk; Endometrial cancer risk; Hormonal contraception; Ovarian cancer risk

Mesh:

Substances:

Year:  2019        PMID: 31014508     DOI: 10.1016/j.critrevonc.2019.03.001

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  7 in total

1.  Allicin induces cell cycle arrest and apoptosis of breast cancer cells in vitro via modulating the p53 pathway.

Authors:  Guzhalinuer Maitisha; Mutalifu Aimaiti; Zechong An; Xinxia Li
Journal:  Mol Biol Rep       Date:  2021-10-09       Impact factor: 2.316

2.  Contraception in chronic kidney disease: a best practice position statement by the Kidney and Pregnancy Group of the Italian Society of Nephrology.

Authors:  Rossella Attini; Gianfranca Cabiddu; Benedetta Montersino; Linda Gammaro; Giuseppe Gernone; Gabriella Moroni; Domenico Santoro; Donatella Spotti; Bianca Masturzo; Isabella Bianca Gazzani; Guido Menato; Valentina Donvito; Anna Maria Paoletti; Giorgina Barbara Piccoli
Journal:  J Nephrol       Date:  2020-03-12       Impact factor: 3.902

3.  Exploring the Mechanism of Baicalin Intervention in Breast Cancer Based on MicroRNA Microarrays and Bioinformatics Strategies.

Authors:  Anqi Ge; Lifang Liu; Xian'guang Deng; Jun Luo; Yanghua Xu
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-20       Impact factor: 2.629

Review 4.  Breast Cancer Risk with Progestin Subdermal Implants: A Challenge in Patients Counseling.

Authors:  Ghada Mohammed; Noha A Mousa; Iman M Talaat; Haya Ibrahim; Maha Saber-Ayad
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-17       Impact factor: 5.555

Review 5.  Epigenetics and environment in breast cancer: New paradigms for anti-cancer therapies.

Authors:  Chitra Thakur; Yiran Qiu; Yao Fu; Zhuoyue Bi; Wenxuan Zhang; Haoyan Ji; Fei Chen
Journal:  Front Oncol       Date:  2022-09-15       Impact factor: 5.738

6.  [Epidemiology and clinical features of patients with breast cancers hospitalized in the Department of Oncology in Fianarantsoa, Madagascar from 2011 to 2018].

Authors:  Mampionona Ranaivomanana; Nomeharisoa Rodrigue Emile Hasiniatsy; Hajanirina Rakotomahenina; Florine Rafaramino
Journal:  Pan Afr Med J       Date:  2021-03-15

Review 7.  Screening and Prevention for High-Grade Serous Carcinoma of the Ovary Based on Carcinogenesis-Fallopian Tube- and Ovarian-Derived Tumors and Incessant Retrograde Bleeding.

Authors:  Isao Otsuka; Takuto Matsuura
Journal:  Diagnostics (Basel)       Date:  2020-02-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.